A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis

被引：20

作者：

Mascarenhas, J. ^{[1
]}

Kosiorek, H. ^{[2
]}

Prchal, J. ^{[3
]}

Yacoub, A. ^{[4
]}

Berenzon, D. ^{[5
]}

Baer, M. R. ^{[6
]}

Ritchie, E. ^{[7
]}

Silver, R. T. ^{[7
]}

Kessler, C. ^{[8
]}

Winton, E. ^{[9
]}

Finazzi, M. C. ^{[10
]}

Rambaldi, A. ^{[10
,11
]}

Vannucchi, A. M. ^{[12
]}

Leibowitz, D. ^{[13
]}

Rondelli, D. ^{[14
]}

Arcasoy, M. O. ^{[15
]}

Catchatourian, R. ^{[16
]}

Vadakara, J. ^{[17
]}

Rosti, V. ^{[18
]}

Hexner, E. ^{[19
]}

Kremyanskaya, M. ^{[1
]}

Sandy, L. ^{[1
]}

Tripodi, J. ^{[20
]}

Najfeld, V. ^{[20
]}

Farnoud, N. ^{[21
]}

Salama, M. E. ^{[22
]}

Weinberg, R. S. ^{[23
]}

Rampal, R. ^{[21
]}

Goldberg, J. D. ^{[24
,25
]}

Mesa, R. ^{[26
]}

Dueck, A. C. ^{[2
]}

Hoffman, R. ^{[1
]}

机构：

[1] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA

[2] Mayo Clin, Scottsdale, AZ USA

[3] Univ Utah, Sch Med, Div Hematol, Salt Lake City, UT USA

[4] Univ Kansas, Canc Ctr, Kansas City, KS USA

[5] Wake Forest Univ, Med Ctr, Wake Forest Hlth, Comprehens Canc Ctr, Winston Salem, NC 27101 USA

[6] Univ Maryland, Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA

[7] Weill Cornell Med Coll, New York, NY USA

[8] Georgetown Univ, Med Ctr, Washington, DC 20007 USA

[9] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA

[10] Azienda Socio Sanitaria Terr Papa Giovanni XXIII, Hematol, Bergamo, Italy

[11] Univ Milan, Dept Oncol, Milan, Italy

[12] Univ Florence, AOU Careggi, Ctr Res & Innovat Myeloproliferat Neoplasms, CRIMM, Florence, Italy

[13] Palo Alto Med Fdn Sutter Hlth, Oncol Dept, Sunnyvale, CA USA

[14] Univ Illinois, Div Hematol Oncol, Chicago, IL USA

[15] Duke Univ, Sch Med, Durham, NC USA

[16] John H Stroger Jr Hosp Cook Cty Chicago, Oncol Dept, Chicago, IL USA

[17] Geisinger Med Ctr, Danville, PA 17822 USA

[18] IRCCS Policlin San Matteo Fdn, Lab Biochem Biotechnol & Adv Diag, Ctr Study Myelofibrosis, 19 Viale Golgi, I-27100 Pavia, Italy

[19] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[20] Icahn Sch Med Mt Sinai, Dept Pathol & Med, New York, NY 10029 USA

[21] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA

[22] Mayo Med Labs, Rochester, MN USA

[23] New York Blood Ctr, New York, NY 10021 USA

[24] NYU, Sch Med, Dept Populat Hlth, New York, NY USA

[25] NYU, Sch Med, Dept Environm Med, New York, NY USA

[26] UT Hlth San Antonio Canc Ctr, San Antonio, TX USA

来源：

LEUKEMIA | 2019年 / 33卷 / 12期

关键词：

MYELOPROLIFERATIVE NEOPLASMS;

D O I：

10.1038/s41375-019-0524-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2974 / 2978

页数：5

共 50 条

[31] Prospective evaluation of pulmonary vascular involvement in asymptomatic patients with polycythemia vera and essential thrombocythemia
Le Bras, F.
Lamberto, C.
Laperche, T.
Valeyre, D.
Richalet, J. P.
Fenaux, P.
Nines, H.
Kiladjian, J. J.
[J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 240 - 240
[32] Pegylated Interferon-ALFA-2A (PEG-IFN-α-2A; PEGASYS) Therapy Renders High Clinical and Molecular Response Rates in Patients with Essential Thrombocythemia (ET) and Polycythemia VERA (PV)
Quintas-Cardania, Alfonso
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
Cortes, Jorge
Richie, Marie Ann
Borthakur, Gautam
Verstovsek, Srdan
[J]. BLOOD, 2008, 112 (11) : 246 - 246
[33] Limited effects on JAK2 mutational status after pegylated interferon α-2b therapy in polycythemia vera and essential thrombocythemia
Samuelsson, Jan
Mutschler, Manuel
Birgegard, Gunnar
Gram-Hansen, Poul
Bjorkholm, Magnus
Pahl, Heike L.
[J]. HAEMATOLOGICA, 2006, 91 (09) : 1281 - 1282
[34] Thrombosis in patients with polycythemia vera and essential thrombocythemia is not associated with factor V Leiden
Ruggeri, M
Castaman, G
Tosetto, A
Missiaglia, E
Rodeghiero, F
[J]. THROMBOSIS AND HAEMOSTASIS, 1997, : PS186 - PS186
[35] LEUKOCYTOSIS IS A RISK FACTOR FOR RECURRENT THROMBOSIS IN PATIENTS WITH POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA
De Stefano, V.
Za, T.
Rossi, E.
Vannucchi, A. M.
Ruggeri, M.
Elli, E.
Mico, C.
Tieghi, A.
Cacciola, R.
Santoro, C.
Gerli, G.
Vianelli, N.
Guglielmelli, P.
Pieri, L.
Scognamiglio, F.
Rodeghiero, F.
Pogliani, E. M.
Finazzi, G.
Gugliotta, L.
Leone, G.
Barbui, T.
[J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 361 - 361
[36] Experience with oral interferon-alpha in patients with essential thrombocythemia and polycythemia vera
Ouintas-Cardama, Alfonso
Verstovsek, Srdan
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (09) : 859 - 859
[37] A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis
Colaizzo, Donatella
Amitrano, Lucio
Tiscia, Giovanni L.
Grandone, Elvira
Guardascione, Maria Anna
Margaglione, Maurizio
[J]. BLOOD, 2007, 110 (07) : 2768 - 2769
[38] Compassionate Use of Ropeginterferon-Alfa-2b/P1101 for Treatment of High Risk Polycythemia Vera and Essential Thrombocythemia Patients Previously Controlled on Pegylated Interferon-Alfa-2a/Pegasys®
Gilreath, Jeffrey A.
Tashi, Tsewang
Kim, Soo Jin
Hickman, Kimberly
Prchal, Josef T.
[J]. BLOOD, 2018, 132
[39] Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trials
Silver, Richard T.
Hasselbalch, Hans Carl
[J]. HEMATOLOGY, 2016, 21 (07) : 387 - 391
[40] ALPHA-2A INTERFERON THERAPY AND ANTIBODY-FORMATION IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA-VERA WITH THROMBOCYTOSIS
TORNEBOHMROCHE, E
MERUP, M
LOCKNER, D
PAUL, C
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 1995, 48 (03) : 163 - 167

← 1 2 3 4 5 →